Mechanisms for HLA-DQ mediated disease protection and susceptibility

HLA-DQ 介导的疾病保护和易感性机制

基本信息

项目摘要

DESCRIPTION (provided by applicant): Type 1 diabetes (T1D) is an autoimmune metabolic disease characterized by destruction of pancreatic beta cells. Among numerous chromosomal regions that are linked to disease risk, the HLA locus has by far the strongest disease association. In particular, subjects who are heterozygous for HLA- DQA1*0301/DQB1*0302 (DQ8) and HLA-DQA1*0501/DQB1*0201 (DQ2) have the highest risk. In contrast, HLA- DQA1*0102/DQB1*0602 (DQ6) is associated with disease protection. While these genetic aspects are well established, the functional mechanisms by which DQ molecules confer disease protection or susceptibility remain relatively unresolved. We propose to directly examine the role of DQ restricted T cells in T1D pathogenesis and protection from disease. This work, which will apply unique reagents and new technologies and extensive collections of DQ-restricted T cell clones and DQ-transfected cell lines will have the following specific aims: Aim 1: To delineate the functional mechanisms of DQ mediated diabetes susceptibility. Aim 2: To delineate the functional mechanisms of DQ mediated diabetes protection. Aim 3: To directly examine the role of DQ restricted T cells in the pathogenesis of T1D. Utilizing DQ2, DQ8, DQ2/8 and DQ6 monomers and multimers and cutting edge techniques such as ex vivo tetramer enrichment and high throughput transcript analysis, we will identify the distinct functional attributes conferred y susceptible HLA-DQ that lead to the breakdown of self-tolerance and opposing attributes conferred by protective HLA-DQ that restore tolerance. We expect that these attributes will include IL-2 and TCR signaling, antigen presentation, and cytokine profile. Utilizing samples from one of the world's largest T1D registry and a formidable collection of longitudinal samples, we will utilize a matched case-control design that is powered (expected power >90 percent) to compare the ability of DQ and DR auto-reactivity to predict T1D status. A secondary attempt will be made to establish the degree of correlation between DQ and DR auto-reactivity. We expect that HLA-DQ responses will provide a more meaningful correlation than HLA-DR responses. Completion of this study will illuminate important early events in the progression of T1D, suggesting important new avenues for therapy and providing a novel biomarker for disease monitoring. PUBLIC HEALTH RELEVANCE: Recent studies have identified numerous genes that are linked to type 1diabetes (T1D), but HLA genes have by far the strongest association with this disease. Utilizing samples from one of the world's largest T1D patient registries and applying unique technologies, we will directly examine the functional role of these genes in T1D. These observations will illuminate important early events in disease progression, providing a new biomarker and suggesting important new avenues for therapy.
描述(申请人提供):1型糖尿病(T1D)是一种自身免疫性代谢性疾病,以胰岛β细胞破坏为特征。在众多与疾病风险相关的染色体区域中,到目前为止,人类白细胞抗原基因座与疾病的相关性最强。特别是,人类白细胞抗原-DQA1*0301/DQB1*0302(DQ8)和人类白细胞抗原-DQA1*0501/DQB1*0201(DQ2)杂合子的风险最高。相反,人类白细胞抗原-DQA1*0102/DQB1*0602(DQ6)与疾病保护相关。虽然这些遗传因素已经得到了很好的证实,但DQ分子提供疾病保护或易感性的功能机制仍然相对未解。我们建议直接研究DQ限制性T细胞在T1D发病机制和疾病保护中的作用。这项工作将应用独特的试剂和新技术,并广泛收集DQ限制性T细胞克隆和DQ转基因细胞系,其具体目的如下:目的1:阐明DQ介导的糖尿病易感性的作用机制。目的2:阐明DQ介导的糖尿病保护作用机制。目的:直接探讨DQ限制性T细胞在T1D发病机制中的作用。利用DQ2、DQ8、DQ2/8和DQ6单体和多聚体以及体外四聚体浓缩和高通量转录分析等前沿技术,我们将识别导致自身耐受崩溃的易感HLA-DQ赋予的不同功能属性,以及保护性HLA-DQ赋予的恢复耐受的相反属性。我们预计这些属性将包括IL-2和TCR信号、抗原呈递和细胞因子谱。利用来自世界上最大的T1D登记机构之一的样本和强大的纵向样本收集,我们将利用匹配的病例对照设计来比较DQ和DR自动反应性预测T1D状态的能力。将进行第二次尝试,以确定DQ和DR自动反应性之间的相关程度。我们期望人类白细胞抗原-DQ反应将比人类白细胞抗原-DR反应提供更有意义的相关性。这项研究的完成将阐明T1D进展过程中的重要早期事件,为治疗提供重要的新途径,并为疾病监测提供新的生物标志物。 公共卫生相关性:最近的研究已经确定了许多与1型糖尿病(T1D)相关的基因,但到目前为止,人类白细胞抗原基因与这种疾病的相关性最强。利用来自世界上最大的T1D患者登记之一的样本并应用独特的技术,我们将直接检查这些基因在T1D中的功能作用。这些观察将阐明疾病进展中的重要早期事件,提供一个新的生物标记物,并为治疗提供重要的新途径。

项目成果

期刊论文数量(6)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

William W. Kwok其他文献

Longitudinal single cell profiling of epitope specific memory CD4+ T cell responses to recombinant zoster vaccine
针对重组带状疱疹疫苗的表位特异性记忆 CD4+T 细胞反应的纵向单细胞分析
  • DOI:
    10.1038/s41467-025-57562-7
  • 发表时间:
    2025-03-08
  • 期刊:
  • 影响因子:
    15.700
  • 作者:
    Xiaomin Wen;Alex K. Hu;Scott R. Presnell;Emily S. Ford;David M. Koelle;William W. Kwok
  • 通讯作者:
    William W. Kwok
Single cell profiling of circulating autoreactive CD4 T cells from patients with autoimmune liver diseases suggests tissue imprinting
对自身免疫性肝病患者循环自身反应性 CD4 T 细胞的单细胞分析表明存在组织印记
  • DOI:
    10.1038/s41467-025-56363-2
  • 发表时间:
    2025-01-29
  • 期刊:
  • 影响因子:
    15.700
  • 作者:
    Anaïs Cardon;Thomas Guinebretière;Chuang Dong;Laurine Gil;Sakina Ado;Pierre-jean Gavlovsky;Martin Braud;Richard Danger;Christoph Schultheiß;Aurélie Doméné;Perrine Paul-Gilloteaux;Caroline Chevalier;Laura Bernier;Jean-Paul Judor;Cynthia Fourgeux;Astrid Imbert;Marion Khaldi;Edouard Bardou-Jacquet;Laure Elkrief;Adrien Lannes;Christine Silvain;Matthieu Schnee;Florence Tanne;Fabienne Vavasseur;Lucas Brusselle;Sophie Brouard;William W. Kwok;Jean-François Mosnier;Ansgar W. Lohse;Jeremie Poschmann;Mascha Binder;Jérôme Gournay;Sophie Conchon;Pierre Milpied;Amédée Renand
  • 通讯作者:
    Amédée Renand
mouse diabetogenic TCR I.29
小鼠致糖尿病 TCR I.29
  • DOI:
    10.2210/pdb6dfq/pdb
  • 发表时间:
    2019
  • 期刊:
  • 影响因子:
    24.8
  • 作者:
    Yang Wang;T. Sosinowski;A. Novikov;F. Crawford;Janicé White;Niyun Jin;Zikou Liu;Jinhao Zou;D. Neau;Howard W. Davidson;Maki Nakayama;William W. Kwok;L. Gapin;P. Marrack;J. Kappler;S. Dai
  • 通讯作者:
    S. Dai

William W. Kwok的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('William W. Kwok', 18)}}的其他基金

Core-001
核心001
  • 批准号:
    10187732
  • 财政年份:
    2020
  • 资助金额:
    $ 349.12万
  • 项目类别:
Allergen T cell epitopes and phenotypes in peanut allergy
花生过敏中的过敏原 T 细胞表位和表型
  • 批准号:
    10318131
  • 财政年份:
    2020
  • 资助金额:
    $ 349.12万
  • 项目类别:
Core-001
核心001
  • 批准号:
    10318134
  • 财政年份:
    2020
  • 资助金额:
    $ 349.12万
  • 项目类别:
Antigen specific T cell responses to two different strains of SARS-CoV-2
抗原特异性 T 细胞对两种不同 SARS-CoV-2 毒株的反应
  • 批准号:
    10161553
  • 财政年份:
    2020
  • 资助金额:
    $ 349.12万
  • 项目类别:
Project-002
项目-002
  • 批准号:
    10187731
  • 财政年份:
    2020
  • 资助金额:
    $ 349.12万
  • 项目类别:
Project-002
项目-002
  • 批准号:
    10318133
  • 财政年份:
    2020
  • 资助金额:
    $ 349.12万
  • 项目类别:
Allergen T cell epitopes and phenotypes in peanut allergy and immunotherapy
花生过敏和免疫治疗中的过敏原 T 细胞表位和表型
  • 批准号:
    10265786
  • 财政年份:
    2020
  • 资助金额:
    $ 349.12万
  • 项目类别:
Allergen T cell epitopes and phenotypes in peanut allergy and immunotherapy
花生过敏和免疫治疗中的过敏原 T 细胞表位和表型
  • 批准号:
    10089383
  • 财政年份:
    2018
  • 资助金额:
    $ 349.12万
  • 项目类别:
Allergen T cell epitopes and phenotypes in peanut allergy and immunotherapy
花生过敏和免疫治疗中的过敏原 T 细胞表位和表型
  • 批准号:
    10318122
  • 财政年份:
    2018
  • 资助金额:
    $ 349.12万
  • 项目类别:
Allergen T cell epitopes and phenotypes in peanut allergy
花生过敏中的过敏原 T 细胞表位和表型
  • 批准号:
    10318125
  • 财政年份:
    2018
  • 资助金额:
    $ 349.12万
  • 项目类别:

相似海外基金

Defining MHC class I restricted antigen presentation to CD8 T cells in experimental AD and Tauopathy - Supplement
定义实验性 AD 和 Tau 病中 MHC I 类限制性抗原呈递至 CD8 T 细胞 - 补充
  • 批准号:
    10836880
  • 财政年份:
    2023
  • 资助金额:
    $ 349.12万
  • 项目类别:
Targeting MAL2-mediated endocytosis to enhance tumor cell antigen presentation
靶向 MAL2 介导的内吞作用以增强肿瘤细胞抗原呈递
  • 批准号:
    10734324
  • 财政年份:
    2023
  • 资助金额:
    $ 349.12万
  • 项目类别:
Antigen presentation to the adaptive immune system in the choroid contributes to ocular autoimmune disease
脉络膜中的适应性免疫系统的抗原呈递导致眼部自身免疫性疾病
  • 批准号:
    10740465
  • 财政年份:
    2023
  • 资助金额:
    $ 349.12万
  • 项目类别:
Investigation of Target Protein Degradation and Its Effect on Enhancing Cancer-Specific Antigen Presentation by Quantitative Mass Spectrometry
通过定量质谱研究靶蛋白降解及其对增强癌症特异性抗原呈递的影响
  • 批准号:
    23K04971
  • 财政年份:
    2023
  • 资助金额:
    $ 349.12万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Promoting cancer cells' antigen presentation for serving as better targets for T cell immunotherapy
促进癌细胞的抗原呈递,作为 T 细胞免疫治疗的更好靶点
  • 批准号:
    2885451
  • 财政年份:
    2023
  • 资助金额:
    $ 349.12万
  • 项目类别:
    Studentship
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy
结直肠癌免疫治疗中靶向免疫蛋白酶体介导的抗原呈递
  • 批准号:
    10385926
  • 财政年份:
    2022
  • 资助金额:
    $ 349.12万
  • 项目类别:
Lipid Antigen Presentation as a Driver of T2D Inflammation
脂质抗原呈递作为 T2D 炎症的驱动因素
  • 批准号:
    10509043
  • 财政年份:
    2022
  • 资助金额:
    $ 349.12万
  • 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
  • 批准号:
    10704008
  • 财政年份:
    2022
  • 资助金额:
    $ 349.12万
  • 项目类别:
Sex Differences in lipid antigen presentation, impact of lipid antigen presentation on peripheral lipid metabolism
脂质抗原呈递的性别差异,脂质抗原呈递对外周脂质代谢的影响
  • 批准号:
    10818273
  • 财政年份:
    2022
  • 资助金额:
    $ 349.12万
  • 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
  • 批准号:
    10349397
  • 财政年份:
    2022
  • 资助金额:
    $ 349.12万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了